{'fraction_non_alphanumeric': 0.04923076923076923, 'fraction_numerical': 0.04, 'mean_word_length': 4.761061946902655, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparative in-vitro activity of piperacillin-tazobactam against recent clinical isolates, a Dutch national multicentre study.

In this Dutch national survey piperacillin-tazobactam had a MIC90 of < or = 8 mg/L for Enterobacteriaceae (Enterobacter cloacae excluded) and Pseudomonas aeruginosa, 64 mg/L for E. cloacae, and 4 mg/L for Acinetobacter spp. The corresponding MIC90 values for piperacillin alone were < or = 256 mg/L, 256 mg/L, 16 mg/L and 32 mg/L. Only 15 of 93 piperacillin-tazobactam resistant E. cloacae strains were sensitive for ceftazidime, whereas 41 of 93 ceftazidime-resistant E. cloacae were sensitive to piperacillin-tazobactam.